VIVEbiotech Adds Expert Insight to BioProcess International’s Latest Report
Marie Fertin contributes key perspectives on pseudotyping strategies and in vivo lentiviral vector development.
BioProcess International has released its April report “Manufacturing Cell and Gene Therapies,” which opens with an editor’s introduction titled “Getting Therapies into Patients.” This introductory feature, written by Cheryl Scott, brings together perspectives from several industry experts — and VIVEbiotech is proud to share that Marie Fertin’s insights are among them.
In her contribution, Marie highlights that in vivo lentiviral‑vector therapies require highly customized designs, as there is no one‑size‑fits‑all approach. She emphasizes the essential role of pseudotyping in enabling precise targeting, supporting vector stability, and adapting envelopes to the specific needs of each therapy.
Marie also addresses the manufacturing and analytical challenges associated with alternative envelopes, noting that they often deliver lower titers and reduced stability. She underscores the importance of strong process development capabilities, optimized upstream and downstream strategies, and robust analytical methods to ensure scalability, vector integrity, and regulatory compliance.
Her perspective reinforces the critical role of specialized CDMOs in advancing next‑generation LVV programs and supporting the successful translation of advanced therapies to patients.
VIVEbiotech is proud to see Marie’s expertise included in this influential industry discussion.
🔗 Read the full article here.